Clinical use of biomarkers in neurodegenerative disorders / / topic editor Manuel Menéndez-González.
The world has a rapidly ageing population. Neurodegenerative diseases (ND) are strongly linked with age, with older citizens more at risk. Therefore the prevalence of ND is increasing dramatically. The major problem with ND is its difficulty to be diagnosed early. The goal of biomarker characterizat...
Saved in:
: | |
---|---|
TeilnehmendeR: | |
Place / Publishing House: | Lausanne, Switzerland : : Frontiers Media SA,, 2014. ©2014 |
Year of Publication: | 2014 |
Language: | English |
Series: | Frontiers research topics
|
Physical Description: | 1 online resource (122 pages) :; illustrations; digital, PDF file(s). |
Notes: | Bibliographic Level Mode of Issuance: Monograph |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993547664504498 |
---|---|
ctrlnum |
(CKB)3710000000526112 (SSID)ssj0001666301 (PQKBManifestationID)16454632 (PQKBTitleCode)TC0001666301 (PQKBWorkID)15000128 (PQKB)10195562 (WaSeSS)IndRDA00056513 (oapen)https://directory.doabooks.org/handle/20.500.12854/43405 (EXLCZ)993710000000526112 |
collection |
bib_alma |
record_format |
marc |
spelling |
Manuel Menendez-Gonzalez auth Clinical use of biomarkers in neurodegenerative disorders / topic editor Manuel Menéndez-González. Frontiers Media SA 2014 Lausanne, Switzerland : Frontiers Media SA, 2014. ©2014 1 online resource (122 pages) : illustrations; digital, PDF file(s). text txt rdacontent computer c rdamedia online resource cr rdacarrier text file rda Frontiers research topics Bibliographic Level Mode of Issuance: Monograph Includes bibliographical references. The world has a rapidly ageing population. Neurodegenerative diseases (ND) are strongly linked with age, with older citizens more at risk. Therefore the prevalence of ND is increasing dramatically. The major problem with ND is its difficulty to be diagnosed early. The goal of biomarker characterization is to increase certainty that a person has or does not have underlying pathology. During last decades, many research projects where focused on research on biomarkers for ND and this research has blasted into hundreds of scientific articles. However, few studies assessed their use in real clinical practice conditions. This Frontiers Research Topic is focused in the use of biomarkers for neurodegenerative disorders in the clinical setting. Topics include the use of biomarkers in the differential diagnosis of ND, the use of biomarkers to assess the risk of conversion from preclinical conditions, the use of biomarkers to follow up of clinical conditions and studies comparing biomarkers. We challenge to publish studies not only for the more frequent and more studied ND (Alzheimer’s and Parkinson’s diseases), but also for other less known ND such as prion diseases, motor neurone diseases, Huntington’s disease, spinocerebellar ataxia or spinal muscular atrophy among others. Biomarkers are very different in nature - from neuroimaging techniques to molecular parameters to be determined in the biochemical laboratory-. We welcome manuscripts reporting all kind of biomarkers since we wish to join and show together studies from different domains and thus give a perspective throughout the whole spectrum of research on biomarkers for ND. English Neurology. Neurology HILCC Medicine HILCC Health & Biological Sciences HILCC Neurodegenerative Diseases neurodegenerative disease Parkinson's disease MTAi biomarker Huntington's disease CSF biomarkers Frontotemporal dementia (FTD) Menéndez-González, Manuel, editor. 2-88919-400-0 |
language |
English |
format |
eBook |
author |
Manuel Menendez-Gonzalez |
spellingShingle |
Manuel Menendez-Gonzalez Clinical use of biomarkers in neurodegenerative disorders / Frontiers research topics |
author_facet |
Manuel Menendez-Gonzalez Menéndez-González, Manuel, |
author_variant |
m m g mmg |
author2 |
Menéndez-González, Manuel, |
author2_variant |
m m g mmg |
author2_role |
TeilnehmendeR |
author_sort |
Manuel Menendez-Gonzalez |
title |
Clinical use of biomarkers in neurodegenerative disorders / |
title_full |
Clinical use of biomarkers in neurodegenerative disorders / topic editor Manuel Menéndez-González. |
title_fullStr |
Clinical use of biomarkers in neurodegenerative disorders / topic editor Manuel Menéndez-González. |
title_full_unstemmed |
Clinical use of biomarkers in neurodegenerative disorders / topic editor Manuel Menéndez-González. |
title_auth |
Clinical use of biomarkers in neurodegenerative disorders / |
title_new |
Clinical use of biomarkers in neurodegenerative disorders / |
title_sort |
clinical use of biomarkers in neurodegenerative disorders / |
series |
Frontiers research topics |
series2 |
Frontiers research topics |
publisher |
Frontiers Media SA Frontiers Media SA, |
publishDate |
2014 |
physical |
1 online resource (122 pages) : illustrations; digital, PDF file(s). |
isbn |
2-88919-400-0 |
callnumber-first |
R - Medicine |
callnumber-subject |
RC - Internal Medicine |
callnumber-label |
RC365 |
callnumber-sort |
RC 3365 |
illustrated |
Illustrated |
work_keys_str_mv |
AT manuelmenendezgonzalez clinicaluseofbiomarkersinneurodegenerativedisorders AT menendezgonzalezmanuel clinicaluseofbiomarkersinneurodegenerativedisorders |
status_str |
c |
ids_txt_mv |
(CKB)3710000000526112 (SSID)ssj0001666301 (PQKBManifestationID)16454632 (PQKBTitleCode)TC0001666301 (PQKBWorkID)15000128 (PQKB)10195562 (WaSeSS)IndRDA00056513 (oapen)https://directory.doabooks.org/handle/20.500.12854/43405 (EXLCZ)993710000000526112 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Clinical use of biomarkers in neurodegenerative disorders / |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1787551938658697216 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03564cam a2200577 i 4500</leader><controlfield tag="001">993547664504498</controlfield><controlfield tag="005">20230803213815.0</controlfield><controlfield tag="006">a fs d </controlfield><controlfield tag="007">cr#mn#---|||||</controlfield><controlfield tag="008">160829t20142014sz a ob 000 0 eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3710000000526112</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SSID)ssj0001666301</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(PQKBManifestationID)16454632</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(PQKBTitleCode)TC0001666301</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(PQKBWorkID)15000128</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(PQKB)10195562</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(WaSeSS)IndRDA00056513</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/43405</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993710000000526112</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">PQKB</subfield><subfield code="d">UkMaJRU</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC365</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Manuel Menendez-Gonzalez</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Clinical use of biomarkers in neurodegenerative disorders /</subfield><subfield code="c">topic editor Manuel Menéndez-González.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2014</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Lausanne, Switzerland :</subfield><subfield code="b">Frontiers Media SA,</subfield><subfield code="c">2014.</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="a">©2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (122 pages) :</subfield><subfield code="b">illustrations; digital, PDF file(s).</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">text file</subfield><subfield code="2">rda</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Frontiers research topics</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Bibliographic Level Mode of Issuance: Monograph</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The world has a rapidly ageing population. Neurodegenerative diseases (ND) are strongly linked with age, with older citizens more at risk. Therefore the prevalence of ND is increasing dramatically. The major problem with ND is its difficulty to be diagnosed early. The goal of biomarker characterization is to increase certainty that a person has or does not have underlying pathology. During last decades, many research projects where focused on research on biomarkers for ND and this research has blasted into hundreds of scientific articles. However, few studies assessed their use in real clinical practice conditions. This Frontiers Research Topic is focused in the use of biomarkers for neurodegenerative disorders in the clinical setting. Topics include the use of biomarkers in the differential diagnosis of ND, the use of biomarkers to assess the risk of conversion from preclinical conditions, the use of biomarkers to follow up of clinical conditions and studies comparing biomarkers. We challenge to publish studies not only for the more frequent and more studied ND (Alzheimer’s and Parkinson’s diseases), but also for other less known ND such as prion diseases, motor neurone diseases, Huntington’s disease, spinocerebellar ataxia or spinal muscular atrophy among others. Biomarkers are very different in nature - from neuroimaging techniques to molecular parameters to be determined in the biochemical laboratory-. We welcome manuscripts reporting all kind of biomarkers since we wish to join and show together studies from different domains and thus give a perspective throughout the whole spectrum of research on biomarkers for ND.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Neurology.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neurology</subfield><subfield code="2">HILCC</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">HILCC</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Health & Biological Sciences</subfield><subfield code="2">HILCC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Neurodegenerative Diseases</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neurodegenerative disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Parkinson's disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MTAi</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Huntington's disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CSF biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Frontotemporal dementia (FTD)</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Menéndez-González, Manuel,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88919-400-0</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-08-05 10:21:28 Europe/Vienna</subfield><subfield code="d">00</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2015-12-12 16:57:58 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338611880004498&Force_direct=true</subfield><subfield code="Z">5338611880004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338611880004498</subfield></datafield></record></collection> |